In accordance with Rule 2.10 of the Irish Takeover Panel Act, 1997,
Takeover Rules 2013 (the
Irish Takeover Rules),
Osmotica Pharmaceuticals plc (Nasdaq: OSMT)
(
Osmotica or the
Company)
confirms that, as of the close of business on January 27, 2021, the
Company's issued share capital, excluding treasury shares,
consisted of 62,716,982 ordinary shares of US$0.01 each (the
Osmotica Ordinary Shares). The International
Securities Identification Number (ISIN) of the Osmotica Ordinary
Shares is IE00BF2HDL56.
Osmotica confirms that, as of the close of business
on January 27, 2021, there were outstanding 2,527,522 restricted
stock units (the Osmotica Restricted Stock Units)
and 2,893,115 options to purchase Osmotica Ordinary Shares (the
Osmotica Share Options) granted by Osmotica. Upon
vesting, each Osmotica Restricted Stock Unit entitles the holder to
receive one Osmotica Ordinary Share and each Osmotica Share Option
entitles the holder to purchase one Osmotica Ordinary Share at the
applicable exercise price.
Responsibility Statement Required by the
Irish Takeover Rules
The directors of the Company accept responsibility
for the information contained in this announcement. To the best of
the knowledge and belief of the directors (who have taken all
reasonable care to ensure that such is the case) the information
contained in this announcement is in accordance with the facts and
does not omit anything likely to affect the import of such
information.
A copy of this announcement will be available on
the Company's website at www.osmotica.com by no later than noon
(Irish time) on the business day following this announcement. The
content of the Company’s website is not incorporated into, and does
not form part of, this announcement.
Dealing Disclosure
Requirements
Under the provisions of Rule 8.3 of the Irish
Takeover Rules, if any person is, or becomes, "interested"
(directly or indirectly) in 1% or more of any class of "relevant
securities" of Osmotica, all "dealings" in any "relevant
securities" of Osmotica (including by means of an option in respect
of, or a derivative referenced to, any such "relevant securities")
must be publicly disclosed by not later than 3:30 p.m. (Irish time)
on the "business day" following the date of the relevant
transaction. This requirement will continue until the date on which
the "offer period" ends. If two or more persons co-operate on the
basis of any agreement, either express or tacit, either oral or
written, to acquire an "interest" in "relevant securities" of
Osmotica, they will be deemed to be a single person for the purpose
of Rule 8.3 of the Irish Takeover Rules.
A disclosure table, giving details of the companies
in whose "relevant securities" "dealings" should be disclosed can
be found on the Panel's website at www.irishtakeoverpanel.ie.
"Interests in securities" arise, in summary, when a
person has long economic exposure, whether conditional or absolute,
to changes in the price of securities. In particular, a person will
be treated as having an "interest" by virtue of the ownership or
control of securities, or by virtue of any option in respect of, or
derivative referenced to, securities.
Terms in quotation marks are defined in the Irish
Takeover Rules, which can also be found on the Panel’s website. If
you are in any doubt as to whether or not you are required to
disclose a dealing under Rule 8, please consult the Panel’s website
at www.irishtakeoverpanel.ie or contact the Panel on telephone
number +353 1 678 9020 or fax number +353 1 678 9289.
About Osmotica Pharmaceuticals
plc
Osmotica is a fully integrated biopharmaceutical
company focused on the development and commercialization of
specialty products that target markets with underserved patient
populations. The Company has a diverse portfolio consisting of
promoted and non-promoted products, several of which incorporate
Osmotica’s proprietary Osmodex® drug delivery system. RVL
Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary
supporting Upneeq. Vertical Pharmaceuticals, LLC represents the
Company’s diversified branded portfolio and Trigen Laboratories,
LLC represents the Company’s non-promoted products, including
complex generic formulations.
Osmotica has operations in the United States,
Argentina, and Hungary.
Investor and Media Relations for Osmotica
Pharmaceuticals plc
Lisa M. WilsonIn-Site Communications, Inc.T:
212-452-2793E: lwilson@insitecony.com
Osmotica Pharmaceuticals (NASDAQ:OSMT)
Historical Stock Chart
From Apr 2024 to May 2024
Osmotica Pharmaceuticals (NASDAQ:OSMT)
Historical Stock Chart
From May 2023 to May 2024